Medable tapped to accelerate patient enrollment in Ph IV study

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/STILLFX)
(Image: Getty/STILLFX)

Related tags: Medable, Patient recruitment

The University of Pennsylvania School of Medicine is partnering with Medable to accelerate patient enrollment for its Light Treatment Effectiveness study.

The venture-backed company, headquartered in Palo Alto, CA, which has developed a digital clinical trials platform, was selected to help drive enrollment of 1,050 patients across 20-40 sites.

The Phase IV pragmatic study will evaluate home versus office-based narrowband ultraviolet B phototherapy for psoriasis treatment.

“Medable’s technology solution ensures our patient and site facing apps integrate seamlessly into the busy schedules of our patients and researchers, leading to more complete and accurate data collection, as well as better patient enrollment and retention in our study,”​ said Dr. Joel M. Gelfand, lead study investigator, and professor of Dermatology and Epidemiology in the Perelman School of Medicine at University of Pennsylvania.

“We needed a partner that had the technical sophistication and experience necessary to customize the LITE study app to the needs of our patients and researchers, while providing the inter-operability to connect clinicians, researchers, and patients across our different sites,”​ he said in a statement.

Medable also earlier this month joined​ the American Heart Association (AHA) Center for Health Technology and Innovation Innovators Network.

The goal is to develop a ‘Human Heart Digitome,’ which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, Dr. Michelle Longmire, Medable co-founder and CEO, told us at the time.

Additionally, the National Cancer Institute (NCI) awarded the company​ two Fast-Track Small Business Innovation (SBIR​) grants totaling up to $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials.

Related topics: Clinical Development, Phase III-IV

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars